Literature DB >> 6127220

Variability of beta-blocker pharmacokinetics in young volunteers.

D B Jack, C P Quarterman, R Zaman, M J Kendall.   

Abstract

Plasma concentrations of metoprolol, propranolol oxprenolol, acebutolol and its metabolite diacetolol were measured after single oral doses in young health volunteers. In order to assessed the inter- and intra-subject variability the following pharmacokinetic parameters were compared: AUC0(24), Cmax, tmax and t 1/2. The smallest variation in inter-subject variability was seen with oxprenolol and acebutolol: intrasubject variability was more uniform. Female volunteers taking an oral contraceptive generally had higher AUC0(24) and Cmax values than those not. This finding reached statistical significance only for metoprolol AUC0(24).

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6127220     DOI: 10.1007/bf01061375

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

1.  Enhancement of the bioavailability of propranolol and metoprolol by food.

Authors:  A Melander; K Danielson; B Scherstén; E Wåhlin
Journal:  Clin Pharmacol Ther       Date:  1977-07       Impact factor: 6.875

2.  Influence of cimetidine on pharmacokinetics of propranolol.

Authors:  A M Heagerty; M A Donovan; C M Castleden; J F Pohl; L Patel; A Hedges
Journal:  Br Med J (Clin Res Ed)       Date:  1981-06-13

3.  Bioavailability of conventional and slow-release oxprenolol in fasted and nonfasted individuals.

Authors:  C P Dawes; M J Kendall; P G Welling
Journal:  Br J Clin Pharmacol       Date:  1979-03       Impact factor: 4.335

4.  Bioavailability of atenolol formulations.

Authors:  J Mcainsh; W T Simpson; B F Holmes; J Young; S H Ellis
Journal:  Biopharm Drug Dispos       Date:  1980 Oct-Dec       Impact factor: 1.627

5.  Propranolol disposition in renal failure.

Authors:  A J Wood; R E Vestal; C L Spannuth; W J Stone; G R Wilkinson; D G Shand
Journal:  Br J Clin Pharmacol       Date:  1980-12       Impact factor: 4.335

6.  Roles of hepatic blood flow and enzyme activity in the kinetics of propranolol and sotalol.

Authors:  H I Pirttiaho; E A Sotaniemi; R O Pelkonen; U Pitkänen; M Anttila; H Sundqvist
Journal:  Br J Clin Pharmacol       Date:  1980-04       Impact factor: 4.335

7.  Interaction between oral propranolol and hydralazine.

Authors:  A J McLean; H Skews; A Bobik; F J Dudley
Journal:  Clin Pharmacol Ther       Date:  1980-06       Impact factor: 6.875

8.  The effect of impaired renal function on the plasma concentration and urinary excretion of metoprolol metabolites.

Authors:  K J Hoffmann; C G Regårdh; M Aurell; M Ervik; L Jordö
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

9.  Propranolol dynamics in thyrotoxicosis.

Authors:  J Feely; I H Stevenson; J Crooks
Journal:  Clin Pharmacol Ther       Date:  1980-07       Impact factor: 6.875

10.  The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol.

Authors:  C G Regårdh; P Lundborg; B A Persson
Journal:  Biopharm Drug Dispos       Date:  1981 Jan-Mar       Impact factor: 1.627

View more
  22 in total

Review 1.  Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.

Authors:  Peer Tfelt-Hansen; Frederik Nybye Ågesen; Agniezka Pavbro; Jacob Tfelt-Hansen
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

2.  ICI 141,292 (epanolol)--pharmacokinetics after single and repeated oral administration in the elderly with moderate renal impairment.

Authors:  M S Laher; P Crome; G S Rakhra; S I Ankier; I D Cockshott
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Circadian influence on effect of propranolol on exercise-induced tachycardia in healthy subjects.

Authors:  A Fujimura; Y Kumagai; K Sugimoto; H Nakashima; H Kajiyama; A Ebihara; K Ohashi
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  Intra- and intersubject variability: mixed-effects statistical analysis of repeated doses of an angiotensin converting enzyme inhibitor, CGS 16617.

Authors:  G M Kochak; R A Smith; R L Choi; V John; V Tipnis; F Honc; J K deSilva; D J Weidler
Journal:  Pharm Res       Date:  1989-04       Impact factor: 4.200

5.  Inter- and intra-subject variability of nitrendipine and the effects of food.

Authors:  J Lobo; D B Jack; M J Kendall
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

6.  The effect of propranolol on the rise in plasma ammonia during modest exercise.

Authors:  P E Hall; S R Smith; M J Kendall
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  Separate and combined effects of nadolol and nifedipine on the cardiac response to exercise.

Authors:  M R Wilkins; K L Woods; D B Jack; M J Kendall; S J Laugher
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  Beta-adrenoceptor blocker pharmacokinetics and the oral contraceptive pill.

Authors:  M J Kendall; D B Jack; C P Quarterman; S R Smith; R Zaman
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

9.  Influence of ranitidine on plasma metoprolol concentrations.

Authors:  D Jack; M Mitchard; R N Smith
Journal:  Br Med J (Clin Res Ed)       Date:  1983-06-25

Review 10.  Sex-related differences in drug disposition in man.

Authors:  K Wilson
Journal:  Clin Pharmacokinet       Date:  1984 May-Jun       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.